相关实验视频
Updated: Jan 13, 2026

07:20
Inducement and Evaluation of a Murine Model of Experimental Myopia
Published on: January 22, 2019
10.4K
翻译性变化:证据表明低剂量氨酸和近视控制
Simon Backhouse1, Linda Robinson1, Christopher Law1
1School of Medicine, Deakin University, Geelong, Australia.
Clinical & experimental optometry
|January 6, 2026
概括
低剂量氨酸眼滴是儿童近视控制的关键选择,为高剂量治疗提供了更少副作用的替代方案. 本综述探讨了低剂量氨酸对从业人员的好处和缺点.
科学领域:
- 眼科医生 眼科 眼科
- 视光学测量 视光学测量 视光学测量
- 儿科眼科护理 儿科眼科护理
背景情况:
- 近视的患病率在全球范围内不断上升,增加了相关病理的风险.
- 近视控制,专注于预防轴延长,现在是儿童近视的标准护理.
- 药物干预,如阿特罗宾,对于近视管理至关重要.
研究的目的:
- 审查低剂量氨酸 (<0.1%) 在儿科近视控制中的疗效和安全性.
- 为从业人员提供基于证据的方法,考虑低剂量阿特罗宾.
- 为了比较低剂量阿特罗宾与较高度的视觉副作用.
主要方法:
- 关于对近视控制的阿特罗宾研究的文献综述.
- 对出版物的分析和对低剂量阿特罗宾的处方趋势.
- 对疗效和不良事件的临床数据的评估.
主要成果:
- 低剂量氨酸显示出有希望的近视控制效果,与1%的氨酸相比,视觉副作用减少.
- 研究和临床使用低剂量阿特罗宾的研究和临床使用显著增加.
- 循环和水是1%的阿特罗宾的显著副作用,低剂量配方的副作用较小.
结论:
- 低剂量氨酸是儿童近视控制的有效和耐受性良好的选择.
- 医生应考虑低剂量氨酸作为预防近视进展的可行策略.
- 进一步的基于证据的研究支持将低剂量氨酸纳入临床实践.
相关概念视频
Open Angle Glaucoma: Treatment
953
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
953
Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.2K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.6K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.6K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.4K

